PMID- 35196205
OWN - NLM
STAT- MEDLINE
DCOM- 20220408
LR  - 20220531
IS  - 2165-5987 (Electronic)
IS  - 2165-5979 (Print)
IS  - 2165-5979 (Linking)
VI  - 13
IP  - 3
DP  - 2022 Mar
TI  - Circular RNA SET domain protein 3 promotes nasopharyngeal carcinoma 
      proliferation, cisplatin resistance, and protein kinase B / mammalian target of 
      rapamycin pathway activation by modulating microRNA-147a expression.
PG  - 5843-5854
LID - 10.1080/21655979.2022.2036907 [doi]
AB  - Circular RNA (circRNA) plays a crucial role in the establishment and progression 
      of nasopharyngeal carcinoma (NPC). Understanding the role of circRNA in NPC is 
      helpful to find new therapeutic targets for NPC. The purpose of this study was to 
      explore the effects of circRNA SET domain protein 3 (circSETD3) on protein kinase 
      B (Akt)/ mammalian target of rapamycin (mTOR) signaling pathway and cisplatin 
      (DDP) resistance to NPC and explore its downstream mechanism. The results showed 
      that circSETD3 was upregulated in NPC tissues and was related to DDP resistance 
      to NPC. Functional experiments revealed that circSETD3 knockdown inhibited NPC 
      proliferation and increased DDP sensitivity and apoptosis rate. The promotion 
      effect of circSETD3 overexpression on NPC proliferation and DDP resistance and 
      inhibition effect on apoptosis was reversed by elevated miR-147a. CircSETD3 
      knockdown or miR-147a overexpression prevented Akt/mTOR pathway's activation. In 
      terms of the mechanism, circSETD3 acted as a sponge for miR-147a. 
      Xenotransplantation experiments showed that knockdown circSETD3 or DDP treatment 
      could restrain tumor growth, and the effect of DDP was enhanced by knockdown of 
      circSETD3. In conclusion, the results of this study confirm that circSETD3 
      promotes NPC proliferation and DDP resistance by regulating miR-147a, and 
      circSETD3/miR-147a axis may serve as a potential therapeutic target for NPC in 
      the future.
FAU - Deng, Gang
AU  - Deng G
AD  - Department of Otorhinolaryngology, Wuhan No. 1 Hospital of Hubei Province, Wuhan 
      City, HuBei Province, China.
FAU - Wang, Fei
AU  - Wang F
AD  - Department of Otorhinolaryngology, People's Hospital of Qinghai Province, Xining 
      City, QingHai Province, China.
FAU - Song, YiSa
AU  - Song Y
AD  - Department of Otorhinolaryngology, People's Hospital of Qinghai Province, Xining 
      City, QingHai Province, China.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Bioengineered
JT  - Bioengineered
JID - 101581063
RN  - 0 (MIRN147 microRNA, human)
RN  - 0 (MicroRNAs)
RN  - 0 (RNA, Circular)
RN  - EC 2.1.1.- (Histone Methyltransferases)
RN  - EC 2.1.1.43 (SETD3 protein, human)
RN  - EC 2.7.11.1 (Proto-Oncogene Proteins c-akt)
RN  - EC 2.7.11.1 (TOR Serine-Threonine Kinases)
RN  - Q20Q21Q62J (Cisplatin)
SB  - IM
MH  - Cell Line, Tumor
MH  - Cell Proliferation/genetics
MH  - Cisplatin/pharmacology
MH  - Drug Resistance, Neoplasm/genetics
MH  - Histone Methyltransferases
MH  - Humans
MH  - *MicroRNAs/genetics
MH  - Nasopharyngeal Carcinoma/genetics/metabolism
MH  - *Nasopharyngeal Neoplasms/metabolism
MH  - Proto-Oncogene Proteins c-akt/metabolism
MH  - *RNA, Circular/genetics
MH  - TOR Serine-Threonine Kinases/genetics/metabolism
PMC - PMC8973767
OTO - NOTNLM
OT  - CircSETD3
OT  - cisplatin resistance
OT  - microRNA-147a
OT  - nasopharyngeal carcinoma
COIS- No potential conflict of interest was reported by the author(s).
EDAT- 2022/02/24 06:00
MHDA- 2022/04/09 06:00
PMCR- 2022/02/23
CRDT- 2022/02/23 17:11
PHST- 2022/02/23 17:11 [entrez]
PHST- 2022/02/24 06:00 [pubmed]
PHST- 2022/04/09 06:00 [medline]
PHST- 2022/02/23 00:00 [pmc-release]
AID - 2036907 [pii]
AID - 10.1080/21655979.2022.2036907 [doi]
PST - ppublish
SO  - Bioengineered. 2022 Mar;13(3):5843-5854. doi: 10.1080/21655979.2022.2036907.